Compare Gilead Sciences, Inc. (GILD) vs HSBC Holdings plc (HSBC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs HSBC Holdings plc — how do they compare? Gilead Sciences, Inc. trades at $133.13 (market cap $163.51B), while HSBC Holdings plc trades at $100.33 (market cap $334.99B). The key difference: HSBC Holdings plc is far larger — about 2× Gilead Sciences, Inc.'s market cap, and HSBC Holdings plc pays the higher dividend (3.73%). Which is the better fit depends on your goals.
| GILD | HSBC | |
|---|---|---|
Market Cap | $163.51B | $334.99B |
Sector | Health | Technology |
52-Week High | $155.80 | $100.46 |
52-Week Low | $108.22 | $61.30 |
Enterprise Value | $178.05B | — |
Dividend Yield | 2.49% | 3.73% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $130.04, down 1.04% on the day, with technical indicators showing a bearish bias while fundamentals remain strong. The company has beaten earnings expectations for three consecutive quarters, maintains robust profitability with a 30.99% net income margin, and recently secured FDA and European Commission approvals for expanded use of its oncology drug Trodelvy. Analyst consensus remains overwhelmingly positive with a $152.83 price target representing 17.5% upside potential.
The outlook for GILD is favorable with strong earnings momentum, expanding oncology portfolio, and solid cash generation, though risks include patent expirations, competitive pressures in HIV treatments, and recent negative cash flow trends. The stock presents a compelling opportunity for investors seeking exposure to a profitable biopharmaceutical company with growth catalysts, supported by Wall Street's bullish sentiment and recent regulatory wins.
HSBC trades at $100.05, up 0.81% on the day and near its 52-week high. The stock shows a bullish technical trend with strong moving average support. Fundamentally, the bank reported $22.29 billion net income in 2025 with a robust 30.81% net margin, though Q1 2026 earnings missed expectations. Recent news highlights strategic moves, including a potential Turkey exit and AI partnerships.
Outlook remains cautiously optimistic with a mixed analyst consensus (38.1% Buy). Key opportunities include efficiency gains from AI initiatives and a solid dividend. Risks involve execution of restructuring, regulatory penalties, and macroeconomic pressures on global banking.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About HSBC Holdings plc
HSBC is one of the world's largest banking and financial services organizations. It serves customers worldwide through four global businesses: Retail, Commercial, Global Banking, and Private Banking.
Read more on HSBC →
